BioSpace News Archive

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate tumor targeting platform, announced that the U.S. Food and Drug Administration has provided the green light regarding the Investigational New Drug application for CBX-12, the company’s lead therapeutic candidate.

AzurRx BioPharma, Inc. announced it has completed enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, announced it has appointed Eliseo O. Salinas, M.D., MSc, as the company’s chief research & development officer.

Innoforce Pharmaceuticals, a biopharmaceutical innovation and partnership company, announced the completion of a 625M CNY Series A financing, which follows a 170M CNY Pre-A financing completed in June 2020.

Landmark REVITA-T2Di study will assess potential of outpatient Revita DMR treatment to eliminate need for daily insulin

Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology Indications and Solid Tumors

FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies

Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021.